Stem Cell Mobilization with and without Plerixafor: A Comparative Analysis

Abstract

A Abstract Patients scheduled for high-dose chemotherapy who fail to mobilize a sufficient number of hematopoietic stem cells have a poor prognosis. Since 2008 the CXCR4-inhibitor plerixafor is available to improve stem cell collection and to reduce the number of failed mo -bilizers. The of Hodgkin Lymphoma (HD) and Multiple Myeloma (MM) was evaluated (group A). All patients received G-CSF with or without chemotherapy for mobilization. This group was matched by age, sex and diagnosis to 47 proven poor mobilizers receiving plerixafor (group B). In group A, 92.9% diagnosed with NHL and all patients diagnosed with MM and HD gathered more than 2.0 × 10^6 CD34+ cells/kg BW. In group B, 64.3% of the NHL patients, 88.2% of the patients diagnosed with MM and all patients with HD were able to collect the defined minimum of CD34+ cells. In total, 74.5% of poor mobilizing patients who received plerixafor gathered more than 2.0 × 10^6/kg BW CD34+ cells. Transplanted cells engrafted in both cohorts; how- ever, in NHL and MM patients, engraftment of white blood cells and platelets were significant earlier in group A than in group B. In conclusion, only 4.3% of patients failed first mobilization at -tempt. For these limited number of patients plerixafor is a valuable additive.